Gnome Sciences

Executive Summary

Gnome Sciences is a San Francisco-based molecular pathology and biology laboratory services company founded in 2019. Operating a CLIA-certified facility, the company provides comprehensive preclinical and clinical research services to pharmaceutical and biotechnology partners. Its offerings include histopathology, gene expression analysis, biomarker multiplex assays, and pharmacogenomic testing, positioning it as a central lab for tissue-based and biomarker-driven research. By focusing on high-quality, reproducible data, Gnome Sciences supports drug development programs from early discovery through clinical trials, aiming to accelerate precision medicine initiatives. Despite being a private, pre-clinical stage company with no disclosed funding or valuation, Gnome Sciences has carved a niche in the competitive CRO landscape. Its core strength lies in its specialized assay capabilities and CLIA certification, which are critical for biomarker validation and regulatory submissions. The company's growth trajectory depends on securing ongoing collaborations with biopharma firms and expanding its test menu to meet evolving client needs. With no debt or equity financing visible, Gnome Sciences likely operates on a service-based revenue model, making its financial stability contingent on sustained project wins. The company's future hinges on scaling operations and building a reputation for reliable, high-throughput biomarker analysis.

Upcoming Catalysts (preview)

• Q3 2026Securing a multi-year master service agreement with a top-20 pharmaceutical company40% success
• Q4 2026Launch of a novel multiplex biomarker panel for immuno-oncology50% success
• Q2 2026Expansion of laboratory capacity to support high-throughput sample processing70% success